International Journal of Clinical Oncology

, Volume 24, Issue 6, pp 694–697 | Cite as

Adjuvant therapy in renal cell carcinoma: the perspective of urologists

  • Annabel SpekEmail author
  • B. Szabados
  • J. Casuscelli
  • C. Stief
  • M. Staehler
Original Article



Until recently, there was no approved adjuvant therapy (AT) for renal cell carcinoma (RCC) unless sunitinib was approved in the US. We evaluated clinical opinion and estimated use regarding different treatment options and patient selection of AT in RCC patients based on current scientific data and individual experience in Germany.


We conducted an anonymous survey during a national urology conference in 01/2017. Answers of 157 urologists treating RCC patients could be included. Questions were related to practice setting, treatment of RCC, follow-up strategy, physicians’ personal opinion and individually different important parameters regarding S-TRAC and ASSURE-trial.


82% were office based. 67% were located in larger cities. 83% reported that nephron-sparing surgery (NSS) was performed in tumors with diameter < 4 cm. Follow-up was done mainly in concordance with guideline recommendations. 68% treated an average of 2.9 patients/year with systemic therapy. Therapy was predominantly advocated using sunitinib (94%). Urologists were informed about S-TRAC and ASSURE-trial. For 47%, reported hazard ratio is the most important parameter to understand trial results followed by overall survival (OS) in 46%, disease-free survival in 38%, and results of other trials in 34%. The most convincing parameter to decide on AT is OS (69%). 62% placed their confidence in ASSURE over STRAC-trial. 44% would use AT for 12 months. Nodal involvement was the most common denominator for use of AT. 82% favor sunitinib as AT.


A minority of urologists would use AT and are more confident in ASSURE-trial. Reluctance of prescribing AT mainly is based on lack of OS data and conflicting trial results.


Renal cell carcinoma High-risk carcinoma Adjuvant therapy Statistical data interpretation Targeted therapy 


Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical standards

This manuscript does not contain any studies with human participants or animals performed by any of the authors.


  1. 1.
    Institute NC (2017) SEER stat facts sheets: kidney and renal pelvis cancer 2017. Accessed 21 July 2018
  2. 2.
    Ljungberg B, Bensalah K, Canfield S et al (2015) EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol 67(5):913–924CrossRefGoogle Scholar
  3. 3.
    Patard JJ, Kim HL, Lam JS et al (2004) Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. J Clin Oncol 22(16):3316–3322CrossRefGoogle Scholar
  4. 4.
    Leibovich BC, Blute ML, Cheville JC et al (2003) Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma. Cancer 97(7):1663–1671CrossRefGoogle Scholar
  5. 5.
    Haas NB, Manola J, Uzzo RG et al (2016) Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet 387(10032):2008–2016CrossRefGoogle Scholar
  6. 6.
    Janowitz T, Welsh SJ, Zaki K et al (2013) Adjuvant therapy in renal cell carcinoma-past, present, and future. Semin Oncol 40(4):482–491CrossRefGoogle Scholar
  7. 7.
    Pal SK, Haas NB (2014) Adjuvant therapy for renal cell carcinoma: past, present, and future. Oncologist 19(8):851–859CrossRefGoogle Scholar
  8. 8.
    Ravaud A, Motzer RJ, Pandha HS et al (2016) Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy. N Engl J Med 375(23):2246–2254CrossRefGoogle Scholar
  9. 9.
    Motzer RJ, Jonasch E, Agarwal N et al (2017) Kidney cancer, version 2.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw JNCCN 15(6):804–834CrossRefGoogle Scholar
  10. 10.
    U. S. Food and Drug Administration (2017) FDA approves sunitinib malate for adjuvant treatment of renal cell carcinoma. Accessed 2018
  11. 11.
    Lenis AT, Donin NM, Johnson DC et al (2018) Adjuvant therapy for high risk localized kidney cancer: emerging evidence and future clinical trials. J Urol 199(1):43–52CrossRefGoogle Scholar
  12. 12.
    Kroeger N, Stenzl A, Burchardt M et al (2017) Adjuvant treatment of high-risk renal cell carcinoma: leaving the desert? Eur Urol 71(5):695–696CrossRefGoogle Scholar
  13. 13.
    Motzer RJ, Haas NB, Donskov F et al (2017) Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with localized or locally advanced renal cell carcinoma. J Clin Oncol 35(35):3916–3923CrossRefGoogle Scholar
  14. 14.
    Battle D, Hammers H, Jonasch E et al (2018) MP66-17 patients perspectives on adjuvant therapy in renal cell carcinoma. J Urol 199(4):e875Google Scholar
  15. 15.
    Meissner MA, McCormick BZ, Karam JA et al (2018) Adjuvant therapy for advanced renal cell carcinoma. Expert Rev Anticancer Ther 18(7):663–671. CrossRefGoogle Scholar
  16. 16.
    Gross-Goupil M, Kwon TG, Eto M et al (2018) Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial. Ann Oncol 29(12):2371–2378CrossRefGoogle Scholar

Copyright information

© Japan Society of Clinical Oncology 2019

Authors and Affiliations

  1. 1.Department of UrologyLudwig Maximilian UniversityMunichGermany

Personalised recommendations